Evercore ISI added West Pharmaceutical (WST) to the firm’s “Tactical Outperform” list, telling investors that Q2 marked an inflection point. Destocking is over and West is well-positioned into 2026, argues the analyst, who believes the growth algorithm should come back. The firm has an Outperform rating and $350 price target on West shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical price target raised to $275 from $260 at Barclays
- Strong Market Position and Growth Potential Justify Buy Rating for West Pharmaceutical Services
- West Pharmaceutical initiated with a Buy at Rothschild & Co Redburn
- West Pharmaceutical Announces Departure of Senior VP
- AI Analyst Is Bullish on These 3 “Strong Buy” Healthcare Stocks, 9/2/25